A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis. ad hoc Study Group.

G Finazzi, T Barbui
{"title":"A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis. ad hoc Study Group.","authors":"G Finazzi,&nbsp;T Barbui","doi":"10.1007/BF02900709","DOIUrl":null,"url":null,"abstract":"<p><p>The clinical records of 103 Italian patients with inherited thrombophilia and thrombosis were reviewed to estimate the incidence of thrombotic recurrences and major bleeding complications according to the different duration of oral anticoagulant prophylaxis (OAP). The incidence of the first thrombotic recurrence was 2.9, 7.4 and 10.8 x 100 patients/year, respectively, in subjects receiving lifelong OAP, stopping OAP after a mean of 9 months (range 1-30 months) or not receiving OAP. The probability to remain free from thrombotic recurrences in patients undergoing lifelong OAP, as estimated by the Kaplan-Meier method, was significantly higher in comparison with untreated patients (p less than 0.001), but did not reach the statistical significance in comparison with patients who stopped prophylaxis. The incidence of further thrombotic recurrences was 1.2, 21.1 and 22.3 x 100 patients/year, respectively, in the three groups defined above. The difference between patients who prolonged indefinitely OAP vs those who stopped or did not receive OAP was statistically significant (p = 0.003). Two intracranial bleedings, one of which fatal, were observed in patients undergoing lifelong OAP, whereas no major bleeding complications occurred in the other two groups. Our study supports the recommendations to continue indefinitely OAP in patients with inherited thrombophilia and recurrent thrombosis, but suggests caution in starting lifelong prophylaxis soon after the first thrombotic event in all patients.</p>","PeriodicalId":76092,"journal":{"name":"La Ricerca in clinica e in laboratorio","volume":"20 4","pages":"245-52"},"PeriodicalIF":0.0000,"publicationDate":"1990-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02900709","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Ricerca in clinica e in laboratorio","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02900709","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

The clinical records of 103 Italian patients with inherited thrombophilia and thrombosis were reviewed to estimate the incidence of thrombotic recurrences and major bleeding complications according to the different duration of oral anticoagulant prophylaxis (OAP). The incidence of the first thrombotic recurrence was 2.9, 7.4 and 10.8 x 100 patients/year, respectively, in subjects receiving lifelong OAP, stopping OAP after a mean of 9 months (range 1-30 months) or not receiving OAP. The probability to remain free from thrombotic recurrences in patients undergoing lifelong OAP, as estimated by the Kaplan-Meier method, was significantly higher in comparison with untreated patients (p less than 0.001), but did not reach the statistical significance in comparison with patients who stopped prophylaxis. The incidence of further thrombotic recurrences was 1.2, 21.1 and 22.3 x 100 patients/year, respectively, in the three groups defined above. The difference between patients who prolonged indefinitely OAP vs those who stopped or did not receive OAP was statistically significant (p = 0.003). Two intracranial bleedings, one of which fatal, were observed in patients undergoing lifelong OAP, whereas no major bleeding complications occurred in the other two groups. Our study supports the recommendations to continue indefinitely OAP in patients with inherited thrombophilia and recurrent thrombosis, but suggests caution in starting lifelong prophylaxis soon after the first thrombotic event in all patients.

103例意大利遗传性血栓和血栓患者口服抗凝预防的回顾性研究。特设研究小组。
本文回顾了意大利103例遗传性血栓形成患者的临床记录,根据口服抗凝预防(OAP)的不同持续时间估计血栓复发和主要出血并发症的发生率。在接受终身OAP治疗、平均9个月(1-30个月)后停止OAP治疗或未接受OAP治疗的患者中,首次血栓复发率分别为2.9、7.4和10.8 x 100例/年。Kaplan-Meier方法估计,终身OAP患者无血栓复发的概率显著高于未治疗的患者(p < 0.001),但与停止预防的患者相比,未达到统计学意义。在上述三组中,进一步血栓复发的发生率分别为1.2、21.1和22.3 x 100例/年。无限期延长OAP的患者与停止或未接受OAP的患者之间的差异具有统计学意义(p = 0.003)。在终身OAP患者中观察到两次颅内出血,其中一次是致命的,而在其他两组中没有发生重大出血并发症。我们的研究支持对遗传性血栓和复发性血栓患者无限期继续OAP治疗的建议,但建议在所有患者首次血栓事件发生后不久开始终身预防。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信